FinancialNewsletterPress releases

Q3 Interim Report January – March 2026

Hamlet Biopharma

|

May 21, 2026

Related Documents

HBP_Q3_25/26_EN_260522.pdf

Recent posts

Press release – Lund, June 10th, 2026 – Continued success for the new anti-infective therapies developed by Hamlet BioPharma

June 10, 2026

Pressrelease – Lund, 8 juni, 2026 – Utökning av Hamlet BioPharmas kliniska samarbeten med ledande amerikanskt universitet

June 8, 2026

Q3 Interim Report January – March 2026

May 22, 2026

Press release – Lund, May 21st, 2026 – Monthly investor meeting on the 22nd of May when Hamlet BioPharma is releasing it’s Q3 report

May 21, 2026

Press release – Lund, May 21st, 2026 – Monthly investor meeting on the 22nd of May when Hamlet BioPharma is releasing it’s Q3 report

Pressrelease – Lund, 8 juni, 2026 – Utökning av Hamlet BioPharmas kliniska samarbeten med ledande amerikanskt universitet

An innovative pharmaceutical company with a broad and strong portfolio of projects for the treatment of cancer and infections.

Hamlet BioPharma AB
Klinikgatan 32
SE-222 42 Lund
info@hamletbiopharma.com
Org. no. 556568-8958

Subscribe to receive
Pressreleases and Newsletters

© 2026

Hamlet BioPharma.